Acadia Pharmaceuticals Inc Expected To Post Earnings Of 30 Cents A Share: Earnings Preview

Acadia Pharmaceuticals

23/02/2024 21:53

* ACADIA Pharmaceuticals Inc  ACAD.OQ   ACAD.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 27 for the period ending December 31 2023
    * The San Diego California-based  company is expected to
report a
64.0% increase in revenue to $223.785 million from $136.49
million a year ago, according to the mean estimate from 20
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for ACADIA Pharmaceuticals
Inc is
for earnings of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ACADIA
Pharmaceuticals Inc is $35.50​, above​ its last closing price
of $24.85. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.43       -0.43      -0.40     Beat    6.1
 Jun. 30 2023  -0.03       -0.08      0.01      Beat    112.1
 Mar. 31 2023  -0.21       -0.21      -0.27     Missed  -25.8​
 Dec. 31 2022  -0.24       -0.24      -0.26     Missed  -7
 ​​Sep.        -0.20       -0.19      -0.17     Beat    10.3
 30 2022                                                
 Jun. 30 2022  -0.24       -0.25      -0.21     Beat    15.2​
 Mar. 31 2022  -0.67       -0.60      -0.33     Beat    45.1
 Dec. 31 2021  -0.25       -0.24      -0.27     Missed  -13.6
 This summary was machine generated February 23 at 21:53 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)